AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6781586
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who completed first four treatments
Trial: 31622456
Drug: Early ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early ART initiation during TB treatment
Trial: 31622456
Drug: Late ART
RxNorm normalized name: Flavor PCCA Chocolate Artificial (Aldehyde Base)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late ART initiation during TB treatment
Trial: 31622456
Drug: Sequential ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential ART initiation after TB treatment completion
Trial: 23522530
Drug: Phentolamine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine administered at 30 minutes after IAN block
Trial: 23522530
Drug: Phentolamine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine administered at 60 minutes after IAN block
Trial: 23522530
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection at 30 minutes and phentolamine at 60 minutes
Trial: 19267842
Drug: Topical hyaluronic
RxNorm normalized name: hyaluronate Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hyaluronic acid (HA) gel preparation (0.2%)
Trial: 14744178
Drug: Olanzapine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5 to 20 mg/day, most receiving 5 to 10 mg/day)
Trial: 11099053
Drug: 50 microg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg/ml hr-EGF
Trial: 11099053
Drug: 10 microg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg/ml hr-EGF
Trial: 8445427
Drug: Intensive systemic
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive systemic therapy with either IT MTX or CXRT
Trial: 8445427
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic therapy with CXRT
Trial: 8445427
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic therapy with IT MTX
Trial: 8445427
Drug: CXRT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXRT in patients 10 years or older with intensive systemic therapy
Trial: 8445427
Drug: IT MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT MTX in patients 10 years or older with intensive systemic therapy
Trial: 8445427
Drug: IT MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT MTX in patients less than 10 years of age with intensive systemic therapy
Trial: 8445427
Drug: CXRT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXRT in patients less than 10 years of age with intensive systemic therapy
Trial: 29788996
Drug: Guided web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided web-based intervention with treatment as usual and immediate access to the web-based intervention
Trial: 29788996
Drug: Waiting control
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting control condition with treatment as usual and delayed access to the web-based intervention
Trial: 27338551
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine spray (group L)
Trial: 22759255
Drug: SGP‐HA (≤1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGP‐HA (≤1.5 mL/lip)
Trial: 20041473
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) with quinidine pre-treatment
Trial: 17922883
Drug: MDI +
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI + SP (metered dose inhaler plus spacer)
Trial: 31232920
Drug: CCR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCR with PBM Therapy (CR-PBM)
Trial: 31232920
Drug: CCR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCR and placebo PBM Therapy (CR-PlaceboPBM)
Trial: 28715325
Drug: Inference-based framework
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inference-based framework for privacy-preserving similarity search in Hamming space; specific dosage and duration not applicable.
Trial: 26968623
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (investigational drug)
Trial: 26968623
Drug: Control drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drug (mometasone furoate)
Trial: 18269128
Drug: Chloroform (CHCl3)
DrugBank: Chloroform (DB11387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroform (CHCl3) treatment
Trial: 18269128
Drug: Chloroform (CHCl3)
DrugBank: Chloroform (DB11387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroform (CHCl3) + Silane (sil) treatment
Trial: 18269128
Drug: Sandblasting (sand)
RxNorm normalized name: SAND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasting (sand) + Silane (sil) treatment
Trial: 18269128
Drug: Silane (sil)
RxNorm normalized name: silane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silane (sil) treatment
Trial: 12191661
Drug: Scotchbond 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scotchbond 1 in combination with Rely X ARC resin cement (3M)
Trial: 1087955
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both regimens
Trial: 31623611
Drug: Processed red
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Processed red meat with high drinking water nitrate (3.7 mg/kg bodyweight)
Trial: 31623611
Drug: Unprocessed white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unprocessed white meat with high drinking water nitrate (3.7 mg/kg bodyweight)
Trial: 27654259
Drug: Metformin (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (conventional antidiabetic doses)
Trial: 24463451
Drug: teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teriparatide (20 μg recombinant human parathyroid hormone)
Trial: 20719253
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 μg twice daily for 12 months
Trial: 16170180
Drug: Chemoradiotherapy (CRT);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (CRT); concurrent cisplatin (25 mg/m2 on days 1 to 4) on weeks 1, 4, and 7 of RT and adjuvant cisplatin (20 mg/m2 on days 1 to 4) and fluorouracil (1,000 mg/m2 on days 1 to 4) every 4 weeks for three cycles after completion of RT
Trial: 7613554
Drug: Moguisteine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moguisteine (100 mg t.i.d.)
Trial: 7613554
Drug: Codeine 15
RxNorm normalized name: codeine 15 MG
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine 15 mg (t.i.d.)
Trial: 7613554
Drug: Codeine 30
RxNorm normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine 30 mg (t.i.d.)
Trial: 576296
Drug: Constant intravenous
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant intravenous infusion of regular insulin (2 units/hour)
Trial: 576296
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (two thirds of daily maintenance doses)
Trial: 576296
Drug: Preoperative NPH
RxNorm normalized name: INSULIN,NPH,BEEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative NPH insulin and 1 unit/hour insulin administration
Trial: 29209926
Drug: Prophylactic phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic phenylephrine infusion (50 μg·min‐1, titrated)
Trial: 29209926
Drug: Phenylephrine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine bolus dosing (100 μg)
Trial: 24048950
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of irbesartan 300 mg film-coated tablet
Trial: 18219299
Drug: High-sodium diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium diet with ACE inhibitor (HS-ACEi; enalapril 20 mg/day)
Trial: 8694217
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine 2 ml with 1:200,000 adrenaline
Trial: 1398272
Drug: Intracervical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical prostaglandin E2 gel (0.5 mg)
Trial: 4025314
Drug: Bovine heparin
RxNorm normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine heparin #1
Trial: 4025314
Drug: Bovine heparin
RxNorm normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine heparin #2
Trial: 4025314
Drug: Porcine gut
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine gut heparin
Trial: 21194762
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose tirofiban
Trial: 15892438
Drug: Generic health-related
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic health-related instruments administered first (SF-36 followed by HADS)
Trial: 15892438
Drug: Vision-targeted instruments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vision-targeted instruments administered first (NEI-VFQ followed by SST-VPVS)
Trial: 12684289
Drug: BPV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPV plus conventional therapy
Trial: 10098826
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of generalized anxiety, panic, and dysthymic disorders
Trial: 9345409
Drug: Copolymer I
RxNorm normalized name: Copolymer I (synthetic peptide)
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copolymer I (20 mg daily subcutaneous injection)
Trial: 2050174
Drug: Peroral captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroral captopril (25 mg)
Trial: 6410442
Drug: tryptophan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tryptophan (1 g)
Trial: 31010449
Drug: Integrated, exposure-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated, exposure-based treatment (COPE)
Trial: 31010449
Drug: Non-exposure-based, SUD-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-exposure-based, SUD-only treatment (RP)
Trial: 27028980
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg/d, up-titrated to 30 mg/d)
Trial: 24690571
Drug: Cerebral perfusion
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral perfusion pressure-targeted therapy (n = 55)
Trial: 24690571
Drug: Intracranial pressure-targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracranial pressure-targeted therapy (n = 55)
Trial: 22240353
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg RES capsule daily for 3 months
Trial: 17549295
Drug: Low-dose HT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose HT (1 mg 17ss-oestradiol + 0.5 mg norethisterone acetate) (n = 50)
Trial: 17549295
Drug: Conventional-dose HT
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose HT (2 mg 17ss-oestradiol and 1 mg NETA) (n = 50)
Trial: 17549295
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg) (n = 51)
Trial: 17549295
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg) (n = 51)
Trial: 9863873
Drug: Monotherapy arms
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monotherapy arms (zidovudine, zalcitabine, didanosine)
Trial: 9863873
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies (zidovudine, zalcitabine, didanosine)
Trial: 8568176
Drug: Hysterosonography with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysterosonography with sterile saline injection using a novel catheter
Trial: 6201083
Drug: Dextran infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran infusion with hapten blockade (monovalent dextran-1)
Trial: 16284385
Drug: Broccoli sprouts
RxNorm normalized name: broccoli sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprouts infusion containing 400 micromol glucoraphanin
Trial: 16284385
Drug: Broccoli sprouts
RxNorm normalized name: broccoli sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprouts infusion containing < 3 micromol glucoraphanin
Trial: 31464548
Drug: Single SUI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SUI treatment (Group 1)
Trial: 31464548
Drug: Two SUI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two SUI treatments (Group 2)
Trial: 23210360
Drug: Microcurrent reflexotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent reflexotherapy (MCRT) combined with cortexin therapy, massage, and remedial gymnastics
Trial: 21197917
Drug: Monthly videophone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly videophone healthy-lifestyle education calls (Control)
Trial: 17081398
Drug: Elevated fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated fibrinogen (fibrinogen level > 4.0 g/L, n = 81)
Trial: 17081398
Drug: Control fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control fibrinogen (fibrinogen level < or = 4.0 g/L, n = 104)
Trial: 17081398
Drug: Elevated hs-CRP
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated hs-CRP (hs-CRP > 3.0 mg/L, n = 86)
Trial: 17081398
Drug: Control hs-CRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control hs-CRP (hs-CRP < or = 3.0 mg/L, n = 99)
Trial: 17081398
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of elevated fibrinogen and hs-CRP
Trial: 12681023
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) added to 2.5 g/day of metformin (MET)
Trial: 10971048
Drug: Galantamine 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 32 mg/day
Trial: 10971048
Drug: Galantamine 24
RxNorm normalized name: galantamine 24 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 24 mg/day (12-month study)
Trial: 8997651
Drug: 0.2% hexetidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% hexetidine spray
Trial: 1546121
Drug: Moclobemide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (150 mg, increased to 450 mg if necessary)
Trial: 1546121
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg, increased to 200 mg if necessary)
Trial: 31917233
Drug: Post-surgical targeted
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-surgical targeted antibiotic therapy for 2 weeks
Trial: 29328007
Drug: Intravenous hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydration (0.9% NaCl)
Trial: 26677057
Drug: Intact casein
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact casein infusion
Trial: 26677057
Drug: Casein hydrolysate
RxNorm normalized name: casein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein hydrolysate infusion
Trial: 24841647
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution instilled into the pelvic cavity (R-Group)
Trial: 19087330
Drug: Multidisciplinary group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary group treatment (Go4it)
Trial: 16160575
Drug: Frialit‐2 implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frialit‐2 implants or IMZ Twin Plus implants
Trial: 11329114
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate (800 mg daily)
Trial: 26054119
Drug: Chlortetracycline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlortetracycline treatment
Trial: 26054119
Drug: Chlortetracycline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlortetracycline + beclomethasone treatment
Trial: 26054119
Drug: Beclomethasone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone treatment
Trial: 11040246
Drug: Lacidipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (4 mg once daily for 4 weeks)
Trial: 1801333
Drug: Oral chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chloroquine (nasogastric tube)
Trial: 1801333
Drug: Intramuscular chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular chloroquine (3.5 mg/kg 8-hourly)
Trial: 6591740
Drug: Diatrizoate (290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diatrizoate (290 mg I/ml)
Trial: 24681813
Drug: Multiple treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple treatment framework with different variants emphasizing monetary and non-monetary benefits and costs
Trial: 23610561
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate infusion (5.1 mmol/kg for 24 hours)
Trial: 23610561
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride infusion (5.1 mmol/kg for 24 hours)
Trial: 21480703
Drug: Low-dose control
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose control condition
Trial: 16984383
Drug: Oral bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral bovine lactoferrin (bLF) at a dose of 1.8 g daily for 12 weeks
Trial: 11074684
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care with manual therapy
Trial: 11074684
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care with manual therapy (four or more maneuvers)
Trial: 27893820
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg once daily for three days
Trial: 1638586
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg daily for three days
Trial: 1638586
Drug: TMP/SMX 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMX 160 mg/800 mg twice daily for seven days
Trial: 6703672
Drug: Apalcillin (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalcillin (2-g dose, intravenous)
Trial: 6703672
Drug: Piperacillin (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (2-g dose, intravenous)
Trial: 24299662
Drug: EGCG (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (300 mg/d)
Trial: 17494794
Drug: Moli1901 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moli1901 (2.5 mg/d)
Trial: 16645534
Drug: Methyltestosterone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyltestosterone (2.5 mg)
Trial: 16645534
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone therapy (placebo)
Trial: 10606936
Drug: FPND 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPND 400 microg twice daily (b.i.d.)
Trial: 10606936
Drug: FPND 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPND 400 microg once daily (o.d.)
Trial: 10606936
Drug: FPND 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPND 400 microg once daily (o.d.) and FPND 400 microg twice daily (b.i.d.)
Trial: 8891846
Drug: Levosulpiride (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride (25 mg tid)